Edward T Mathers - Net Worth and Insider Trading

Edward T Mathers Net Worth

The estimated net worth of Edward T Mathers is at least $302 Million dollars as of 2024-10-18. Edward T Mathers is the 10% Owner of Savara Inc and owns about 24,471,264 shares of Savara Inc (SVRA) stock worth over $88 Million. Edward T Mathers is the Director, 10% Owner of MBX Biosciences Inc and owns about 3,614,486 shares of MBX Biosciences Inc (MBX) stock worth over $87 Million. Edward T Mathers is also the 10% Owner of Korro Bio Inc and owns about 1,090,793 shares of Korro Bio Inc (KRRO) stock worth over $85 Million. Besides these, Edward T Mathers also holds Monte Rosa Therapeutics Inc (GLUE) . Details can be seen in Edward T Mathers's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Edward T Mathers has not made any transactions after 2024-09-16 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Edward T Mathers

To

Edward T Mathers Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Edward T Mathers owns 15 companies in total, including Inozyme Pharma Inc (INZY) , Akouos Inc (AKUS) , and Rhythm Pharmaceuticals Inc (RYTM) among others .

Click here to see the complete history of Edward T Mathers’s form 4 insider trades.

Insider Ownership Summary of Edward T Mathers

Ticker Comapny Transaction Date Type of Owner
INZY Inozyme Pharma Inc 2020-07-23 director
AKUS Akouos Inc 2020-06-25 director
RYTM Rhythm Pharmaceuticals Inc 2017-10-04 director
LIMIT LIMIT 2019-05-07 director
LIMIT LIMIT 2019-07-17 director
LIMIT LIMIT 2016-06-29 director
LIMIT LIMIT 2020-04-02 director
LIMIT LIMIT 2018-07-25 director
LIMIT LIMIT 2023-07-17 10 percent owner
LIMIT LIMIT 2021-04-08 director
LIMIT LIMIT 2021-06-24 10 percent owner
LIMIT LIMIT 2021-06-28 10 percent owner
LIMIT LIMIT 2022-06-08 director
LIMIT LIMIT 2023-01-01 director
LIMIT LIMIT 2024-04-22 10 percent owner

Edward T Mathers Latest Holdings Summary

Edward T Mathers currently owns a total of 4 stocks. Among these stocks, Edward T Mathers owns 24,471,264 shares of Savara Inc (SVRA) as of July 17, 2023, with a value of $88 Million and a weighting of 29.13%. Edward T Mathers owns 3,614,486 shares of MBX Biosciences Inc (MBX) as of September 16, 2024, with a value of $87 Million and a weighting of 28.72%. Edward T Mathers also owns 1,090,793 shares of Korro Bio Inc (KRRO) as of April 22, 2024, with a value of $85 Million and a weighting of 28.22%. The other 1 stocks Monte Rosa Therapeutics Inc (GLUE) have a combined weighting of 13.94% among all his current holdings.

Latest Holdings of Edward T Mathers

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
SVRA Savara Inc 2023-07-17 24,471,264 3.60 88,096,550
MBX MBX Biosciences Inc 2024-09-16 3,614,486 24.03 86,856,099
KRRO Korro Bio Inc 2024-04-22 1,090,793 78.26 85,365,460
GLUE Monte Rosa Therapeutics Inc 2021-06-28 7,692,298 5.48 42,153,793

Holding Weightings of Edward T Mathers


Edward T Mathers Form 4 Trading Tracker

According to the SEC Form 4 filings, Edward T Mathers has made a total of 1 transactions in Savara Inc (SVRA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Savara Inc is the acquisition of 333,333 shares on July 17, 2023, which cost Edward T Mathers around $999,999.

According to the SEC Form 4 filings, Edward T Mathers has made a total of 1 transactions in MBX Biosciences Inc (MBX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in MBX Biosciences Inc is the acquisition of 500,000 shares on September 16, 2024, which cost Edward T Mathers around $8 Million.

According to the SEC Form 4 filings, Edward T Mathers has made a total of 1 transactions in Korro Bio Inc (KRRO) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Korro Bio Inc is the acquisition of 17,857 shares on April 22, 2024, which cost Edward T Mathers around $999,992.

More details on Edward T Mathers's insider transactions can be found in the Insider Trading History of Edward T Mathers table.

Insider Trading History of Edward T Mathers

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Edward T Mathers Trading Performance

GuruFocus tracks the stock performance after each of Edward T Mathers's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Edward T Mathers is 2.06%. GuruFocus also compares Edward T Mathers's trading performance to market benchmark return within the same time period. The performance of stocks bought by Edward T Mathers within 3 months outperforms 2 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Edward T Mathers's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Edward T Mathers

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 2 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 1.07 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -0.73 LIMIT LIMIT LIMIT LIMIT LIMIT

Edward T Mathers Ownership Network

Ownership Network List of Edward T Mathers

No Data

Ownership Network Relation of Edward T Mathers

Insider Network Chart

Edward T Mathers Owned Company Details

What does Inozyme Pharma Inc do?

Who are the key executives at Inozyme Pharma Inc?

Edward T Mathers is the director of Inozyme Pharma Inc. Other key executives at Inozyme Pharma Inc include director & 10 percent owner Robert Lorne Hopfner , COO Matthew Winton , and See Remarks Henric Bjorn Bjarke .

Inozyme Pharma Inc (INZY) Insider Trades Summary

Over the past 18 months, Edward T Mathers made no insider transaction in Inozyme Pharma Inc (INZY). Other recent insider transactions involving Inozyme Pharma Inc (INZY) include a net purchase of 1,281,265 shares made by Robert Lorne Hopfner , a net purchase of 833,333 shares made by Pivotal Bioventure Partners Fund I G.p., L.p. , and a net sale of 7,523 shares made by Douglas A Treco .

In summary, during the past 3 months, insiders sold 0 shares of Inozyme Pharma Inc (INZY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 7,523 shares of Inozyme Pharma Inc (INZY) were sold and 2,114,598 shares were bought by its insiders, resulting in a net purchase of 2,107,075 shares.

Inozyme Pharma Inc (INZY)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Inozyme Pharma Inc Insider Transactions

No Available Data

Edward T Mathers Mailing Address

Above is the net worth, insider trading, and ownership report for Edward T Mathers. You might contact Edward T Mathers via mailing address: C/o Medimmune, Inc., One Medimmune Way, Gaithersburg Md 20878.

Discussions on Edward T Mathers

No discussions yet.